Tenet CEO leaving earlier than expected

Trevor Fetter, CEO and chairman on Tenet Healthcare, was scheduled to leaving those roles by March 15, 2018. Instead, he resigned effective Oct. 23, leaving executive chairman Ronald Rittenmeyer in charge as interim CEO.

“I have confidence in Ron’s leadership and Tenet’s management team, so now is the right time for me to step down as CEO,” Fetter said in a statement. “I am grateful for the hard work and dedication of all of Tenet’s employees in building this great company, and it has been an honor to work alongside them.”

Fetter had been with Tenet since 1995, working his way up to president in 2002, CEO in 2003 and chairman in 2015. His departure had first been announced after several weeks of financial turmoil in August, when the company posted a $56 million loss in the second quarter and cut its earnings forecast. The largest shareholder in the company, Glenview Capital Management, then had its two representatives on the board quit, setting up a potential proxy fight.

Tenet responded with a “shareholder rights plan” which would allow other shareholders to buy shares at a 50 percent discount if any investor acquired 4.9 percent or more of the company, setting up a “poison pill” to scare off any proxy battle. Additionally, the company announced it would sell eight hospitals in the U.S. and nine in the U.K., potentially yielding $1 billion for the company.

Already announced sales have included a $170 million deal with Paladian Healthcare for two Philadelphia hospitals, off-loading MacNeal Hospital in Berwyn, Illinois, and seeking buyers for three other hospitals in the Chicago area.

A sale of the company or a breakup along its three main business lines remain possibilities. The Wall Street Journal reported in September Tenet had been meeting with investment bank to discuss its options.

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.